JAC Advance Access first published online on November 13, 2008
This version published online on November 13, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn431
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei
School of Medicine, University of Manchester, 1.800 Stopford Building, Oxford Road, Manchester M13 9PT, UK
Received 4 May 2008; returned 20 June 2008; revised 20 August 2008; accepted 18 September 2008
* Corresponding author. Tel: +44-161-275-5757; Fax: +44-161-275-5656; E-mail: peter.warn{at}manchester.ac.uk
Objectives: The aim of this study was to assess the dose–response of isavuconazole, voriconazole and fluconazole in disseminated Candida tropicalis and Candida krusei infections.
Methods: Mice were immunosuppressed using either one dose [temporarily neutropenic (TN)] or two doses [persistently neutropenic (PN)] of cyclophosphamide. Treatment was started 5 h after infection with oral isavuconazole (6, 15, 30, 60, 90, 120 or 150 mg/kg equivalent active compound), intravenous voriconazole (5, 20 or 40 mg/kg plus grapefruit gavage twice daily) or oral fluconazole (15, 50 or 150 mg/kg) all administered twice daily. Kidney burden was assessed for C. tropicalis, and kidney and brain burden for C. krusei.
Results: Vehicle controls developed a non-lethal infection with high burdens in both models. In the TN models, isavuconazole, voriconazole and fluconazole (>50 mg/kg) reduced kidney burden compared with controls; >60 mg/kg isavuconazole and 50 mg/kg fluconazole were superior to alternative treatments (other than voriconazole 40 mg/kg). Isavuconazole (all doses) reduced brain burden (P < 0.05) in the C. krusei model; fluconazole (all doses) and voriconazole (5 and 20 mg/kg) did not. In the C. krusei kidney burden model, isavuconazole 120 and 150 mg/kg and voriconazole 40 mg/kg were superior to controls and fluconazole. In the C. tropicalis model, PN isavuconazole (all doses), voriconazole (>5 mg/kg) and fluconazole (all doses) reduced kidney burden (P < 0.05). Only isavuconazole (all doses) and 40 mg/kg voriconazole were effective against C. krusei in the brain, isavuconazole and voriconazole reduced tissue burden (P < 0.05). Fluconazole had no significant effect on brain burden even at 150 mg/kg.
Conclusions: Isavuconazole significantly reduced kidney burden in mice infected with C. tropicalis and both kidney and brain burdens in mice infected with C. krusei. Isavuconazole was as effective as voriconazole and much more effective than fluconazole at reducing brain burden.
Key Words: BAL4815 , BAL8557 , antifungal , mouse
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Marine, F. J. Pastor, C. Serena, and J. Guarro Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3585 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Rodriguez, E. Calvo, C. Serena, M. Marine, F. J. Pastor, and J. Guarro Effects of Double and Triple Combinations of Antifungal Drugs in a Murine Model of Disseminated Infection by Scedosporium prolificans Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2153 - 2155. [Abstract] [Full Text] [PDF]
|
|